|Articles|November 5, 2015

Pediatric Drug Development & Therapeutics

Author(s)DIA

DIA’s Editor-in-Chief Stephen P. Spielberg, MD, PhD, FAAP, and Ronald Portman, MD, FAAP, discuss the Pediatric Drug Development & Therapeutics series of articles and how they can help inform the future of pediatric drug development on DIA’s podcast channel, Driving Ideas to Action.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Trending on PharmExec

Pediatric Drug Development & Therapeutics

Related Content

EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval

The New Healthy Aging Imperative and What It Means for Pharma

Reading Between the Lines: Closing the T1D Misdiagnosis Gap

Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

Beyond the Strip: Las Vegas Has a New Kind of Venture in Mind

Trending on PharmExec

EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval

Reading Between the Lines: Closing the T1D Misdiagnosis Gap

Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

The Rise of Direct-to-Patient Models in Pharma: Opportunities and Risks in Bypassing Traditional Distribution Channels

Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics